ImmuPharma Major Opportunity Within Lupuzor Unlocked

ImmuPharma (LON:IMM) announced a major US licensing deal on 28 November 2019 with Avion Pharmaceuticals, a US specialty business that has a focus on Rheumatology, Women’s health (Lupus afflicts women more) Dermatology and other therapeutic areas. Avion have a strong marketing and commercialisation operation (with over 100 specialist sales reps). Avion has exclusively in-licensed Lupuzor™ for the US market for Lupus (SLE) and other indications and agreed to fund an international Phase III clinical trial for up to US$25m. In addition, Avion will pay up to US$70m in milestones and a royalty stream tiered to 17% has been agreed. We have always believed that ImmuPharma could deliver such a successful deal for the US market (given the track record of the previous deal executed with Cephalon). This deal with Avion was aided by the strength of the clinical data (and safety profile) from the Phase III trial announced last year. Our detailed analysis of the respective cohort data, driven by the performance of the peptide in the auto ds-DNA antibody positive patients validated our assumptions of the value of Lupuzor™.

We now see Lupuzor™ as having the ability to generate blockbuster sales in the US (US$1bn+) alone (previously US and EU combined) – which when coupled with a royalty stream of up to 17% on revenues, could see an annual royalty to ImmuPharma’s bottom line of US$170m per year. What is particularly impressive about this deal is not only ImmuPharma’s ability to identify and execute a new licensing partner for Lupuzor™ but also the opportunity available for ImmuPharma to find new distribution and marketing partners outside the US for Lupuzor™, for e.g. in Europe, where a new trial would not even be required given Avion’s funding commitment. This means that there is a distinct possibility that further licensing deals could follow bringing in an attractive additional royalty stream, and additional upfront and milestone payments. Outside of Lupuzor™, we believe that ImmuPharma has the potential to generate news-flow on its other pipeline assets including Nucant and UreKa. Based on the financial assumptions for this deal, and a lower risk profile (reduction in risk premium in our DCF model) we increase our target price (which is 50% discounted) from 76p to 100p / share. BUY.

To read the full Life Sciences Division report, click here

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Immupharma Plc

    More articles like this

    Immupharma Plc

    How to Test for Lupus

    Lupus is a medical condition with an aura of mystery. Symptoms affect each patient differently and can mimic other disorders. There’s no single “lupus test” to pinpoint the disease. Lupus is one of more than 100 known autoimmune

    Immupharma Plc

    ImmuPharma licenses lupus drug Lupuzor

    British pharmaceutical firm ImmuPharma said on Thursday it had signed a licensing and development agreement for Lupuzor, a first-in-class treatment for auto-immune disease Lupus, with U.S. company Avion Pharmaceuticals. Avion and ImmuPharma will co-develop Lupuzor, including

    Immupharma Plc

    ImmuPharma Chairman explains why the Avion deal is so significant

    ImmuPharma plc (LON: IMM) Non-Executive Chairman Tim McCarthy joins DirectorsTalk to discuss a licencing and development agreement with US speciality pharmaceutical company Avion. Tim talks us through the key highlights of the deal, provides background on Avion,

    Immupharma Plc

    ImmuPharma to present at Biotech Showcase™ 2020

    ImmuPharma (LON:IMM), a specialist drug discovery and development company, has announced that it will be presenting at the Biotech Showcase™ 2020, to be held between 13-15 January 2020, at the Hilton, San Francisco Union Square. Dr

    Immupharma Plc

    Selena Gomez’s Lupus Flare Up at AMA’s

    Selena Gomez took to the American Music Awards (AMAs) stage for the first time in two years on Sunday night to perform two new tracks, ‘Lose You To Love Me’ and ‘Look At Her Now’. However, the

    Immupharma Plc

    Selena Gomez opens up on body-shaming comments

    Selena Gomez has admitted to struggling after being “attacked” for gaining weight following her lupus diagnosis. The chart-topping singer, 27, was diagnosed with lupus in 2015 and later underwent a kidney transplant due to complications from

    Immupharma Plc

    Lupus flare-ups could be linked to environmental factors

    Researchers have found that alteration in the environment and atomospheric factors could be associated with organ specific flare-ups of lupus among patients diagnosed with Systemic Lupus Erythematosus (SLE). The study results were presented at the 2019 ACR/ARP Annual Meeting.

    Immupharma Plc

    Lupus: the ‘invisible’ disease

    “Lupus mimics other diseases in your body and the community still doesn’t understand what it is,” says Daniella Djan who is living with the condition. Djan’s life changed irrevocably when she was 18-years-old and diagnosed with

    Immupharma Plc

    Managing Fatigue in Lupus

    Fatigue can be described as a feeling of weariness that is more extreme than simple tiredness. It often includes a lack of both physical and mental (or emotional) energy and motivation. The fatigue that many patients

    Immupharma Plc

    Look At Her Now: Selena Gomez

    Selena Gomez is back, and fans couldn’t be happier. It’s a triumphant return for Selena, who has suffered through health issues and break-ups over the past two years – but nothing can hold this girl down.

    Immupharma Plc

    Living with Lupus

    Another day, another torment. The same will follow the next day — the excruciating pain, inexplicable fatigue, and never-ending drowsiness. This is life with lupus, a rare, chronic autoimmune condition where the body’s immune system starts

    Immupharma Plc

    Lupus: 9 Early Signs that Mean You Have It

    Lupus is a serious disease which causes intense inflammation along with a variety of other symptoms. Each sufferer’s symptoms are quite different. Here, MusicSnake Magazine put together a list of 9 Early Signs that may mean you have lupus. Number One:

    Immupharma Plc

    Lupus and Celiac Disease: What Pharmacists Need to Know

    According to the Lupus Foundation of America, approximately 5 million people globally are affected by lupus and about 16,000 new cases are reported annually. Lupus occurs when the body’s immune system attacks the tissues and organs, which